CL2019001106A1 - Composición para aliviar o tratar el dolor. - Google Patents
Composición para aliviar o tratar el dolor.Info
- Publication number
- CL2019001106A1 CL2019001106A1 CL2019001106A CL2019001106A CL2019001106A1 CL 2019001106 A1 CL2019001106 A1 CL 2019001106A1 CL 2019001106 A CL2019001106 A CL 2019001106A CL 2019001106 A CL2019001106 A CL 2019001106A CL 2019001106 A1 CL2019001106 A1 CL 2019001106A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- pharmaceutical composition
- present
- relieve
- treat pain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000024452 GDNF Human genes 0.000 abstract 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/30—Animals modified by surgical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA ALIVIAR O TRATAR EL DOLOR. UNA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN CONTIENE DOS O MÁS GENES SELECCIONADOS DEL GRUPO QUE CONSISTE EN GAD, IL-10 Y UN GEN QUE CODIFICA GDNF. LA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN EXHIBE UN EXCELENTE EFECTO ANALGÉSICO EN UNA DOSIS MÁS BAJA QUE LA DE LA ADMINISTRACIÓN INDIVIDUAL, YA QUE LOS GENES SE ADMINISTRAN DE FORMA CONJUNTA, LO CUAL PERMITE REDUCIR SUS EFECTOS SECUNDARIOS CONVENCIONALES Y SU TOXICIDAD. POR LO TANTO, LA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN PUEDE RESULTAR ÚTIL PARA ALIVIAR O TRATAR EL DOLOR.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160143519 | 2016-10-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019001106A1 true CL2019001106A1 (es) | 2019-08-16 |
Family
ID=62023801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019001106A CL2019001106A1 (es) | 2016-10-31 | 2019-04-23 | Composición para aliviar o tratar el dolor. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20190255152A1 (es) |
EP (1) | EP3533471B1 (es) |
JP (1) | JP6957614B2 (es) |
KR (2) | KR102445192B1 (es) |
CN (1) | CN110461367B (es) |
AU (1) | AU2017351914B2 (es) |
BR (1) | BR112019008788A2 (es) |
CA (2) | CA3041980C (es) |
CL (1) | CL2019001106A1 (es) |
ES (1) | ES2905227T3 (es) |
RU (1) | RU2725830C1 (es) |
SA (1) | SA519401667B1 (es) |
SG (1) | SG11201903517RA (es) |
WO (1) | WO2018080277A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
CA3180304A1 (en) * | 2020-05-28 | 2021-12-02 | Kenan Christopher GARCIA | Engineered interleukin-10 polypeptides and uses thereof |
CN116981474A (zh) * | 2021-03-12 | 2023-10-31 | 可隆生命科学株式会社 | 用于预防或治疗退行性脑疾病的组合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
CN101203530A (zh) * | 2004-10-28 | 2008-06-18 | 匹兹堡大学高等教育联邦体系 | 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗 |
RU2433825C2 (ru) * | 2004-12-06 | 2011-11-20 | Медисинова, Инк. | Способ лечения невропатической боли и связанных с ней синдромов |
EP1893754A4 (en) * | 2005-05-31 | 2009-01-21 | Neurologix Inc | NEW GLUTAMIC ACID DECARBOXYLASE (GAD) CHIMESES AND USE PROCESSES |
WO2008010637A1 (en) * | 2006-07-19 | 2008-01-24 | Industry-Academic Cooperation Foundation, Yonsei University | Composition for attenuating neuropathic pain comprising a recombinant vector expressing gad65 |
KR20080007968A (ko) * | 2006-07-19 | 2008-01-23 | 연세대학교 산학협력단 | Gad65를 발현하는 재조합 벡터를 포함하는 신경병증성통증 완화용 조성물 |
FI20070808A0 (fi) * | 2007-10-25 | 2007-10-25 | Mart Saarma | GDNF:n silmukointivariantit ja niiden käytöt |
CN101586096A (zh) * | 2008-05-21 | 2009-11-25 | 王尚武 | 一种共表达人源谷氨酸脱羧酶和细胞因子的重组病毒 |
EP2457579A1 (en) * | 2010-11-26 | 2012-05-30 | Technische Universität Dresden | Covalently linked interleukin -10 |
JP5918275B2 (ja) * | 2011-02-08 | 2016-05-18 | アッヴィ・インコーポレイテッド | 変形性関節症及び疼痛の治療 |
KR20170034701A (ko) * | 2015-09-21 | 2017-03-29 | 코오롱생명과학 주식회사 | 통증 치료용 조성물 |
-
2017
- 2017-10-31 BR BR112019008788A patent/BR112019008788A2/pt unknown
- 2017-10-31 CA CA3041980A patent/CA3041980C/en active Active
- 2017-10-31 ES ES17863851T patent/ES2905227T3/es active Active
- 2017-10-31 SG SG11201903517RA patent/SG11201903517RA/en unknown
- 2017-10-31 WO PCT/KR2017/012136 patent/WO2018080277A1/ko unknown
- 2017-10-31 AU AU2017351914A patent/AU2017351914B2/en active Active
- 2017-10-31 RU RU2019116751A patent/RU2725830C1/ru active
- 2017-10-31 US US16/346,170 patent/US20190255152A1/en active Pending
- 2017-10-31 CN CN201780081884.XA patent/CN110461367B/zh active Active
- 2017-10-31 CA CA3123063A patent/CA3123063A1/en active Pending
- 2017-10-31 KR KR1020217026063A patent/KR102445192B1/ko active IP Right Grant
- 2017-10-31 JP JP2019523609A patent/JP6957614B2/ja active Active
- 2017-10-31 EP EP17863851.6A patent/EP3533471B1/en active Active
- 2017-10-31 KR KR1020197011633A patent/KR20190067815A/ko not_active IP Right Cessation
-
2019
- 2019-04-23 CL CL2019001106A patent/CL2019001106A1/es unknown
- 2019-04-28 SA SA519401667A patent/SA519401667B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
CA3041980C (en) | 2023-06-13 |
CN110461367B (zh) | 2023-05-26 |
SA519401667B1 (ar) | 2023-01-11 |
EP3533471A4 (en) | 2020-05-06 |
RU2725830C1 (ru) | 2020-07-06 |
AU2017351914B2 (en) | 2020-09-10 |
KR20190067815A (ko) | 2019-06-17 |
JP6957614B2 (ja) | 2021-11-02 |
JP2019537595A (ja) | 2019-12-26 |
EP3533471B1 (en) | 2022-01-19 |
EP3533471A1 (en) | 2019-09-04 |
US20190255152A1 (en) | 2019-08-22 |
CA3123063A1 (en) | 2018-05-03 |
BR112019008788A2 (pt) | 2019-07-16 |
ES2905227T3 (es) | 2022-04-07 |
AU2017351914A1 (en) | 2019-05-23 |
KR20210107140A (ko) | 2021-08-31 |
CN110461367A (zh) | 2019-11-15 |
KR102445192B1 (ko) | 2022-09-20 |
CA3041980A1 (en) | 2018-05-03 |
SG11201903517RA (en) | 2019-05-30 |
WO2018080277A1 (ko) | 2018-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
CO2018005370A2 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
CL2016003041A1 (es) | Ácidos ribonucleicos bicatenarios aislados, composiciones farmacéuticas que los comprenden y método para inhibir la expresión del gen alas1 basado en la administración de dicha composición. divisional de solicitud 2725-2014. | |
CL2019003091A1 (es) | Terapia de combinación. | |
CL2020000747A1 (es) | Formulaciones de niraparib. | |
UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
CL2019001106A1 (es) | Composición para aliviar o tratar el dolor. | |
CO2019009722A2 (es) | Dendrímeros terapéuticos | |
ECSP20057847A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
BR112018001292A2 (pt) | métodos para melhor liberação de agentes ativos a tumores | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
CL2019001092A1 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas. | |
CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
ECSP23096498A (es) | Restos de administración terapéutica novedosos y usos de estos | |
ECSP18002561A (es) | Sales y profármacos de 1-metil-d-triptófano | |
MX2018000611A (es) | Sistemas mejorados de entrega de nanoparticula. | |
BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina |